The observed incidence of anaphylaxis and serum sickness in patients receiving omalizumab in a tertiary allergy and asthma clinic in Canada
Crossref DOI link: https://doi.org/10.1186/1710-1492-10-S2-A28
Published Online: 2014-12-18
Published Print: 2014-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
MacRae, Megan
Santucci, Stephanie
Karsh, Jacob
Yang, William H
Article History
First Online: 18 December 2014